Endo's Frova Delayed on New-Use Approval
Posted on: Friday, 16 March 2007, 12:00 CDT
U.S. firms Endo and Vernalis said Friday the Food and Drug Administration has extended by three months an application for Frova's expanded use.
The companies said the Food and Drug Administration has notified them it would require another three months to review Endo's supplemental new drug application, in which Endo is seeking approval on a new use for Frova, for the short-term prevention of menstrual migraine.
With the extension, the FDA is expected to complete its review of the application on or before Aug. 19, the companies said.
FDA's need for extra review time is related to the presentation of the data, rather than its content and the agency did not request additional information, the companies stressed.
Endo President and CEO Peter Lankau said the extended review time would have no effect on the company's 2007 financial guidance.
Frova was previously approved for the acute treatment in adults of migraine attacks with or without aura, or subjective symptoms at the onset of a migraine.
Source: United Press International
Related Articles
- Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
- Review of Takeda's Febuxostat New Drug Application Continues Past PDUFA Date
- A Drug Pipeline Report of the Central Nervous System Focusing on Migraines: Major Companies & Clinical Trial Intelligence Included
- FDA to Review ProEthic's Migraine Drug
- ABILIFY(R) (Aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients With Bipolar I Disorder Accepted for Priority Review By the U.S. Food and Drug Administration
- FDA to Review Vernalis Migraine Drug
- Trial Supports Wider Use of Vernalis and Endo's Migraine Drug
- Priority Review for Avanir Involuntary Expression Drug
- Migraine Technology Company Neuralieve Names MedTech Veteran Gary Stroy to Top Post
- GlaxoSmithKline's Topical Antibacterial Retapamulin Accepted for Review By The U.S. Food and Drug Administration
 |
 |
User Comments (0)
RSS Feeds